Evidence map›Paper›PMID 40605085›Full record

ReviewHuman reproduction (Oxford, England)2025

Stem cell-derived gametes: what to expect when expecting their clinical introduction.

Ilse J de Bruin, Merel M Spaander, Simone Harmsen, Rosanne Edelenbosch, M Corrette Ploem, Nina Dartée, Madalena Cardoso Vaz Santos, Mathangi Lakshmipathi, Callista L Mulder, Ans M M van Pelt and 6 more

Abstract readReview
In one paragraph

Review in Human reproduction (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ilse J de BruinDepartment of Developmental Biology, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0001-7459-089X
Merel M SpaanderDepartment of Health Law, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-7137-5462
Simone HarmsenRathenau Institute, The Hague, The Netherlands.ORCID 0000-0001-9745-0910
Rosanne EdelenboschRathenau Institute, The Hague, The Netherlands.ORCID 0000-0002-9460-5523
M Corrette PloemDepartment of Health Law, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1466-0619
Nina DartéeDepartment of Developmental Biology, Erasmus MC, Rotterdam, The Netherlands.
Madalena Cardoso Vaz SantosReproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Mathangi LakshmipathiReproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Callista L MulderReproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-9160-7585
Ans M M van PeltReproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-9155-548X
Willy M BaarendsDepartment of Developmental Biology, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-9179-850X
Susana M Chuva de Sousa LopesDepartment of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-3866-2803
Guido M W R de WertDepartment of Health, Ethics and Society, Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-0410-4902
Seppe SegersDepartment of Philosophy and Moral Sciences, Bioethics Institute Ghent, Ghent University, Ghent, Belgium.ORCID 0000-0001-8231-6487
Geert HamerReproductive Biology Laboratory, Center for Reproductive Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-9583-6796
Ana M Pereira DaoudDepartment of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-0675-8133

Funding

Dutch Organization for Health Research and Development
6 · The paper itself

Abstract

Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.

Indexed as

Germ CellsInduced Pluripotent Stem CellsAnimalsClinical Trials as TopicFemaleHumansMaleReproductive Techniques, Assistedassisted reproductive technologiesclinical applicationethicshumaninduced pluripotent stem cellsin vitro gametogenesislawsocietystem cell-derived gametes

Identifiers

PMID40605085
PMCPMC12408906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.